Advertisement
Advertisement
Trending on CancerNetwork
1
TIP126 TroFuse-011: A Phase 3, Randomized, Open-Label Study of Sacituzumab Tirumotecan With or Without Pembrolizumab vs Treatment of Physician’s Choice for Previously Untreated Locally Recurrent Unresectable or Metastatic Triple-Negative Breast Cancer With PD-L1 Combined Positive Score <10
2
Achieving a “Functional Cure” With Multiple Myeloma Therapy
3
FDA Accepts Protocol Amendment to Phase 3 NANORAY-312 Trial in HNSCC
4
Targeting the CD44-SPP1 Axis: A New Frontier in Bladder Cancer Resistance
5